Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).

被引：0
|
作者：
Hata, Akito
Katakami, Nobuyuki
Takase, Naoto
Kibata, Kayoko
Yamanaka, Yuta
Tamiya, Motohiro
Mori, Masahide
Kijima, Takashi
Morita, Satoshi
Sakai, Kazuko
Nishio, Kazuto
机构：
[1] Kobe Minimally Invas Canc Ctr, Dept Thorac Oncol, Kobe, Hyogo, Japan
[2] Takarazuka City Hosp, Dept Med Oncol, Takarazuka, Hyogo, Japan
[3] Kansai Med Univ Hosp, Dept Thorac Oncol, Hirakata, Osaka, Japan
[4] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[5] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, Toyonaka, Osaka, Japan
[6] Hyogo Coll Med, Dept Resp Med & Hematol, Nishinomiya, Hyogo, Japan
[7] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[8] Kindai Univ, Fac Med, Dept Genome Biol, Sayama, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9117
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study)
    Hata, A.
    Katakami, N.
    Nishino, K.
    Mori, M.
    Yokoyama, T.
    Kurata, T.
    Tachihara, M.
    Takase, N.
    Daga, H.
    Kijima, T.
    Morita, S.
    Sakai, K.
    Nishio, K.
    Satouchi, M.
    Negoro, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study
    Hata, Akito
    Katakami, Nobuyuki
    Takase, Naoto
    Kibata, Kayoko
    Yamanaka, Yuta
    Tamiya, Motohiro
    Mori, Masahide
    Kijima, Takashi
    Morita, Satoshi
    Sakai, Kazuko
    Nishio, Kazuto
    LUNG CANCER, 2024, 197
  • [3] Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: Primary analysis of Gio-Tag Japan, a multicenter prospective observational study
    Takase, N.
    Hata, A.
    Sumi, T.
    Yoshioka, H.
    Fujisaka, Y.
    Ota, T.
    Osugi, J.
    Mitsui, M.
    Morita, R.
    Morita, S.
    Sakai, K.
    Nishio, K.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S811 - S811
  • [4] Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: An exploratory analysis of initial AFA dosage in Gio-Tag Japan, a multicenter prospective observational study
    Hata, A.
    Takase, N.
    Sumi, T.
    Yoshioka, H.
    Fujisaka, Y.
    Ota, T.
    Osugi, J.
    Mitsui, M.
    Morita, R.
    Morita, S.
    Sakai, K.
    Nishio, K.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1659 - S1659
  • [5] Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study)
    Tamiya, M.
    Hata, A.
    Katakami, N.
    Kaji, R.
    Yokoyama, T.
    Toshihiko, K.
    Inoue, T.
    Kimura, H.
    Yano, Y.
    Tamuta, D.
    Morita, S.
    Negoro, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study).
    Hata, Akito
    Katakami, Nobuyuki
    Kaji, Reiko
    Yokoyama, Toshihide
    Kaneda, Toshihiko
    Tamiya, Motohiro
    Inoue, Takako
    Kimura, Hiromi
    Yano, Yukihiro
    Tamura, Daisuke
    Morita, Satoshi
    Negoro, Shunichi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [8] Afatinib plus bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial
    Kobayashi, Nobuaki
    Hashimoto, Hisashi
    Kamimaki, Chisato
    Nagasawa, Ryo
    Tanaka, Katsushi
    Kubo, Sousuke
    Katakura, Seigo
    Chen, Hao
    Hirama, Nobuyuki
    Ushio, Ryota
    Aoki, Ayako
    Nakashima, Kentaro
    Teranishi, Shuhei
    Manabe, Saki
    Watanabe, Hiroki
    Horita, Nobuyuki
    Watanabe, Keisuke
    Hara, Yu
    Yamamoto, Masaki
    Kudo, Makoto
    Piao, Hongmei
    Kaneko, Takeshi
    THORACIC CANCER, 2020, 11 (08) : 2125 - 2129
  • [9] Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC:An ETCTN California cancer consortium phase I study.
    Riess, Jonathan W.
    Groshen, Susan G.
    Reckamp, Karen L.
    Wakelee, Heather A.
    Oxnard, Geoffrey R.
    Padda, Sukhmani Kaur
    Koczywas, Marianna
    Piotrowska, Zofia
    Sholl, Lynette M.
    Paweletz, Cloud P.
    Lau, Christie J.
    Kolesar, Jill
    Mack, Philip C.
    Moscow, Jeffrey
    Janne, Pasi A.
    Lara, Primo
    Newman, Edward M.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
    Bertino, Erin M.
    Gentzler, Ryan D.
    Clifford, Sarah
    Kolesar, Jill
    Muzikansky, Alona
    Haura, Eric B.
    Piotrowska, Zofia
    Camidge, D. Ross
    Stinchcombe, Thomas E.
    Hann, Christine
    Malhotra, Jyoti
    Villaruz, Liza C.
    Paweletz, Cloud P.
    Lau, Christie L.
    Sholl, Lynette
    Takebe, Naoko
    Moscow, Jeffrey A.
    Shapiro, Geoffrey, I
    Janne, Pasi A.
    Oxnard, Geoffrey R.
    CLINICAL CANCER RESEARCH, 2021, 27 (06) : 1604 - 1611
12345